EANS-Adhoc: Sartorius AG / Order intake and sales revenue substantially increased for both divisions | Positive earnings contributed by the Mechatronics Division | Group operating earnings jumped near

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Figures for the First Half of 2010

23.07.2010

In the first half of 2010, order intake for the Sartorius Group
climbed 9.8% (currency-adjusted: +8.4%) from EUR306.4 million to
EUR336.4 million. Sales revenue rose 6.3% (currency-adj.: +5.1%) to
EUR315.2 million from EUR296.5 million a year ago. The Biotechnology
Division received orders valued at EUR221.4 million, up from EUR203.5
million in the previous year, a plus of 8.8% (currency-adj.: +7.4%),
and increased its sales revenue 5.7% (currency-adj.: +4.6%) to
EUR209.1 from EUR197.8 million a year earlier. The Mechatronics
Division posted a significant gain in order intake of 11.8%
(currency-adj.: +10.4%) to EUR115.1 million from EUR102.9 million in
the previous year; its sales revenue grew 7.5% (currency-adj.: +6.1%)
to EUR106.1 million, up from EUR98.7 million a year ago.

Consolidated earnings before interest, taxes and amortization and
adjusted for extraordinary expenses of EUR1.9 million (prev. year:
EUR16.3 mn) — underlying EBITA — surged 47.0% to EUR36.3 million, up
from EUR24.7 million a year earlier; the respective margin rose from
8.3% to 11.5%. The Biotechnology Division contributed an underlying
EBITA of EUR31.5 million, up from EUR28.0 million a year ago, which
means its margin increased from 14.2% to 15.0%. After posting a loss
of EUR3.4 million in the year-earlier period, the Mechatronics
Division contributed a positive result to Group earnings, reporting
an underlying EBITA of EUR4.8 million and improving its profit margin
from -3.4% to 4.5%.

Excluding non-cash amortization, underlying net profit after minority
interest for the first half totals EUR15.9 million (prev. year:
EUR6.4 mn); the respective earnings per share are at EUR0.93, up from
EUR0.37 a year ago.

The results achieved meet our expectations for both divisions and
confirm our outlook for the current fiscal year. This outlook
forecasts sales growth of slightly above 5% in constant currencies
and further improvement of the operating EBITA margin by one to two
percentage points as well as a significantly positive operating cash
flow.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius,
will discuss the results with analysts and investors on Monday, July
26, at 4:00 p.m. Central European Time in a webcast teleconference.
You may dial into the teleconference starting at 3:45 p.m. CET at the
following numbers: Germany +49 (0)69 2222 2245; France +33 (0)1 70 99
42 73; UK +44 (0)20 7138 0824; USA +1 212 444 0481 The dial-in code
is as follows: 4383672 The webcast and presentation can be viewed at
www.sartorius.com.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Andreas Wiederhold

Team Leader Treasury & Investor Relations

Telefon: +49 (0)551 308-1668

E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade